Professor Tariq Enver
Tariq Enver is Director at the University College London Cancer Institute & Professor of Stem Cell Biology. He was elected as an EMBO Fellow in 2009 and elected to the 1000 Talents Programme in China.
His research career has been principally concerned with understanding the mechanisms by which tissue and developmental stage specific gene expression is achieved and regulated with early work focusing on the regulation of the β-globin gene clusters.
His current work deploys post-genomic technologies and mathematical modelling approaches to gain further insight into how blood stem cells are configured in molecular terms, the nature of the pathways involved in their cell fate decisions, and how these may be used in the pursuit of stem cell therapy and how they are corrupted by chimaeric transcription factors associated with human leukaemia.
Daniel Hochhauser is Co-Director of the Cancer Research UK-UCL Centre, Kathleen Ferrier Professor and consultant medical oncologist at University College London.
He has a clinical interest in gastrointestinal oncology. Research areas are in the modulation of DNA interactive agents by novel therapies including inhibition of the epidermal growth factor receptor. Additionally, he has an interest in early phase clinical trials and is currently principal investigator for several novel agents.
After qualifying in medicine from Cambridge and the Royal Free Hospital and postgraduate medical training in London and Oxford, he completed research for a DPhil at the Institute of Molecular Medicine in Oxford. Subsequently he worked as a medical oncology fellow at Memorial Sloan Kettering Cancer Center, New York before appointment as consultant in 1996.
Dr Roy Herbst
Dr Herbst is Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, Director of the Thoracic Oncology Research Program, and Associate Director for Translational Research at Yale Cancer Center (YCC) and Yale School of Medicine, New Haven, CT, USA. He has led phase I development of several new-generation targeted agents for non-small cell lung cancer (NSCLC), including gefitinib, erlotinib, cetuximab, and bevacizumab. He was co-leader of BATTLE-1 and co-leads the BATTLE-2 clinical trial program. He served as co-leader of the Developmental Therapeutics Program for the YCC Support Grant. Herbst’s laboratory work focuses on immunotherapy angiogenesis, EGFR/VEGFR inhibition in NSCLC and targeting KRAS-activated pathways. This work has been translated from preclinical to clinical settings in multiple Phase II and III studies.
Herbst has authored or co-authored more than 300 publications, including peer-reviewed journal articles, abstracts, and book chapters. His work has appeared in many prominent journals, such as the Journal of Clinical Oncology, Clinical Cancer Research, Lancet, and the New England Journal of Medicine. Work published in Nature was awarded the 2015 Herbert Pardes Clinical Research Excellence Award by the Clinical Research Forum.
Herbst was a member of the National Cancer Policy Forum, for which he organized an IOM meeting focused on policy issues in personalized medicine. He is a member of the American Association of Cancer Research, where he chairpersons the Tobacco Task Force, as well as the American Society of Clinical Oncology. He is a fellow of the American College of Physicians and an elected member of the Association of American Physicians. He is vice chair for developmental therapeutics for Southwestern Oncology Group’s (SWOG) Lung Committee, principal investigator of the SWOG 0819 trial, and steering committee chair for the Lung Master Protocol. In 2015, his team at Yale was awarded a lung cancer SPORE by the NCI, and he serves as a principal investigator for the AACR/ Stand Up to Cancer Dream Team grant.